Adenomyosis.

Summary

Oral GnRH antagonists with add-back therapy are emerging as a promising strategy for adenomyosis management. Preliminary studies show encouraging results for symptom control while stabilizing the uterus long-term (up to 104 weeks follow-up reported). They offer advantages over GnRH agonists including dose-dependent estrogen suppression, oral route, and no initial flare effect. Reviews of conservative adenomyosis management highlight these agents as potentially transformative, though additional RCT data specific to adenomyosis are needed.

Summary

Aromatase inhibitors have demonstrated improvement in heavy menstrual bleeding and pelvic pain in adenomyosis patients in clinical studies. They are also being explored as adjunctive pre-treatment with GnRH agonists before frozen embryo transfer in infertile women with adenomyosis. Reviews note their potential role but emphasize that further research is needed to determine their place in adenomyosis management.

Summary

Danazol, a synthetic androgen derivative, has been used off-label for adenomyosis symptom management. Reviews report antiproliferative and anti-inflammatory effects that suggest utility in controlling pain symptoms in adenomyosis patients. It has been administered both orally and via intrauterine devices. Its use is limited by androgenic side effects, but it remains part of the pharmacological armamentarium for adenomyosis when other treatments fail.

Summary

GnRH agonists are effective second-line therapy for adenomyosis, reducing pain, abnormal uterine bleeding, and uterine volume. They are also used pre-treatment before ART to improve pregnancy rates in infertile women with adenomyosis. Single-cell transcriptomic analysis confirmed that GnRHa normalizes immune cell composition and restores epithelial-stromal interactions in adenomyotic uteri. Efficacy is limited by hypogonadal side effects during long-term use.

Summary

Combined oral contraceptives are used off-label for adenomyosis to control pain and abnormal uterine bleeding, though evidence suggests they may be less effective than dienogest or LNG-IUS for this specific condition. Reviews of adenomyosis medical management position them as initial treatment options based on their widespread availability and tolerability, with recommendations to use very-low-dose formulations and avoid ethinyl estradiol when possible in favor of estradiol-based combinations to reduce thromboembolic risk.

Summary

SPRMs including mifepristone, ulipristal acetate, asoprisnil, telapristone acetate, and vilaprisan have been evaluated in clinical trials and observational studies for dysmenorrhea related to uterine diseases including adenomyosis. They demonstrate varying degrees of efficacy in reducing secondary dysmenorrhea associated with adenomyosis through mixed agonist-antagonist effects on progesterone receptors. Their clinical use has been limited by safety concerns (hepatotoxicity with ulipristal acetate), but they remain a potential therapeutic class if appropriate safety parameters are established.

Summary

Multiple systematic and narrative reviews identify the levonorgestrel-releasing intrauterine system as the most effective first-line medical therapy for adenomyosis. It demonstrates efficacy in reducing abnormal uterine bleeding, dysmenorrhea/pelvic pain, and uterine volume. It is considered superior to oral agents due to maintenance of steady-state hormonal levels and contraceptive benefit. Evidence comes from observational studies and non-trial settings with adenomyosis patients diagnosed by imaging or histopathology.

Summary

Dienogest has been evaluated in multiple observational studies and reviews for adenomyosis, showing efficacy in reducing dysmenorrhea, pelvic pain, and uterine volume. It appears superior to combined oral contraceptives for adenomyosis symptom control. Systematic review of pharmacological interventions confirmed its effectiveness alongside LNG-IUS and GnRH analogues, though evidence is primarily from non-RCT settings with adenomyosis patients. Off-label use for adenomyosis; not formally approved for this indication but supported by observational studies and small RCTs.

Summary

In NCT00704912, clomiphene citrate produced dysmenorrhea (n=20), pelvic pain (n=42), abnormal uterine bleeding (n=11), and abdominal pain (n=23) in PCOS women. These uterine-centric pain and bleeding AEs are consistent with effects on adenomyosis-relevant pathways, as clomiphene's estrogen receptor modulation can alter myometrial and junctional zone signaling.

Summary

In NCT00427700 and NCT01607320, raloxifene was studied for ovulation induction in PCOS. The low AE burden (headache n=3, pelvic pain n=1) and its mechanism as a SERM with estrogen-antagonist activity in uterine tissue suggest potential relevance to adenomyosis, which shares estrogen-dependent pathology with endometriosis.

Summary

In NCT02508103, intranasal oxytocin administration in PMDD patients produced uterine cramps (n=2), reflecting direct myometrial oxytocin receptor activation. This uterotonic effect is relevant to adenomyosis, where oxytocin receptor upregulation in ectopic endometrial tissue within the myometrium contributes to dysmenorrhea and uterine hypercontractility. The signal suggests oxytocin pathway engagement that could either exacerbate or modulate adenomyosis-related uterine pain depending on receptor desensitization dynamics.

Summary

In NCT00927095, continuous oral contraceptive use tracked bloating (n=25) and fatigue (n=46) as AEs in PMDD patients. The continuous suppression of ovarian cyclicity and endometrial proliferation achieved by this regimen is also mechanistically relevant to adenomyosis, which shares the estrogen-dependent pathophysiology of endometriosis but involves ectopic endometrial tissue within the myometrium. Continuous OC-mediated hormonal suppression reduces cyclic myometrial stimulation and endometrial-myometrial junction disruption.

Summary

In NCT03749109, quinagolide vaginal ring was studied for lesion reduction in women with endometriosis/adenomyosis. The trial explicitly included adenomyosis in its target population, and reported abdominal distension (n=3) as an AE, a symptom overlapping with adenomyosis presentations. The drug's anti-angiogenic mechanism via dopamine D2 agonism is relevant to adenomyotic lesion biology.

Summary

Anastrozole is an aromatase (CYP19A1) inhibitor approved for breast cancer. CYP19A1 is locally overexpressed in endometriotic lesions where it drives local estrogen biosynthesis independent of ovarian function. ESR1 has the highest overall association with endometriosis (0.670, clinical 0.90), and local aromatase activity in lesions creates an autocrine estrogen loop. Growth regulating estrogen receptor binding 1 (GREB1, genetic association 0.80) is a direct ESR1 transcriptional target that mediates estrogen-driven proliferation.

Summary

Pentoxifylline is a phosphodiesterase inhibitor and adenosine A2 receptor antagonist approved for peripheral vascular disease, in Phase 3 for endometriosis. PDE3/4A inhibition increases intracellular cAMP, which suppresses TNF-α and IL-1α production from peritoneal macrophages. IL-1α has a combined association score of 0.469 with endometriosis (literature 0.84, genetic 0.73). Adenosine A2 receptor blockade further reduces fibrotic and angiogenic signaling relevant to lesion maintenance.

Summary

Prinaberel is a selective estrogen receptor beta (ERβ/ESR2) agonist in Phase 2 for endometriosis. While ESR1 (overall 0.670) drives proliferative and inflammatory effects in endometriosis, ERβ activation opposes ESR1 signaling by inducing anti-proliferative and pro-apoptotic gene programs. ERβ agonism also suppresses Wnt4 pathway activity (Wnt4 genetic association 0.71), which is implicated in endometrial cell fate and progesterone resistance.

Summary

Rosiglitazone is a PPARγ agonist approved for type 2 diabetes, currently in Phase 2 for endometriosis. PPARγ activation directly antagonizes estrogen receptor 1 (ESR1) transcriptional activity via competition for shared coactivators and suppresses NF-κB-driven inflammatory cytokine production including IL-1α (literature score 0.84). ESR1 is the top-scoring target for endometriosis (overall 0.670, clinical 0.90), and IL-1α has a genetic association score of 0.73.

Summary

Bentamapimod is a JNK (c-Jun N-terminal kinase) inhibitor targeting MAPK8/9/10, currently in Phase 2 for endometriosis. JNK signaling is a downstream effector of IL-1α (endometriosis association score 0.469, literature 0.84) and mediates estrogen receptor 1 ligand-independent activation via phosphorylation of AF-1 domains. ESR1 has the highest overall association with endometriosis (0.670). JNK also drives MMP expression critical for tissue invasion by ectopic endometrium.

Summary

Cabergoline is a dopamine D2 receptor agonist approved for hyperprolactinemia. In endometriosis, dopamine D2 receptor activation has been shown to inhibit VEGF-driven angiogenesis via suppression of VEGFR-2 (kinase insert domain receptor, KDR) phosphorylation. KDR has one of the highest genetic association scores for endometriosis (0.93), and cabergoline is already in Phase 2 trials for this condition, suggesting the dopamine-angiogenesis axis is a validated but underappreciated pathway link.

Summary

Tanezumab is an anti-NGF (nerve growth factor) monoclonal antibody in Phase 2 for endometriosis-associated pain. NGF is upregulated in endometriotic lesions where it drives neuroangiogenesis — the co-growth of sensory nerve fibers and blood vessels. This connects to the genetically validated KDR/VEGFR-2 pathway (genetic association 0.93) since NGF and VEGF share reciprocal upregulation in the endometriotic microenvironment. The drug targets pain neuroplasticity rather than hormonal pathways.

Summary

Epelsiban is an oxytocin receptor antagonist developed for preterm labor and IVF implantation support, currently in Phase 2 for adenomyosis. Adenomyosis involves aberrant uterine contractility driven by oxytocin signaling in the junctional zone myometrium. Oxytocin receptor overexpression in adenomyotic tissue drives dysperistalsis, retrograde menstruation, and pain — the oxytocin-myometrial contractility axis is a specific non-hormonal target in this condition.

Summary

Aspirin irreversibly inhibits cyclooxygenase-1 and -2 (PTGS1/PTGS2), the rate-limiting enzymes in prostaglandin biosynthesis. Adenomyotic lesions exhibit marked COX-2 (PTGS2) overexpression driving prostaglandin E2-mediated pain, local estrogen production (PGE2 stimulates aromatase), and angiogenesis. The COX-2/PGE2/aromatase positive feedback loop is a well-characterized pathogenic circuit in adenomyosis.

Summary

Drospirenone uniquely combines progesterone receptor agonism with mineralocorticoid receptor (MR) antagonism. The progesterone receptor has an Open Targets score of 0.215 for adenomyosis (literature 0.37, clinical 0.34). Beyond progestogenic endometrial suppression, MR antagonism addresses aldosterone-mediated water retention, tissue edema, and local renin-angiotensin-aldosterone system (RAAS) activation documented in adenomyotic myometrium.

Summary

Letrozole inhibits CYP19A1 (aromatase), which has an Open Targets association score of 0.207 for adenomyosis with strong literature evidence (0.69). CYP19A1 is overexpressed in adenomyotic lesions, driving local estrogen biosynthesis independent of ovarian production. The genetic and literature convergence on aromatase as a disease-associated target provides a specific molecular rationale for aromatase inhibition in adenomyosis.

Summary

Bromocriptine is a D2-like dopamine receptor agonist listed at Phase 1 for adenomyosis. Prolactin, suppressed by dopamine D2 agonism, is elevated in some adenomyosis patients and promotes local estrogen production and immune dysregulation in endometrial tissue. The dopamine-prolactin-estrogen axis represents a non-obvious neuroendocrine pathway contributing to adenomyotic lesion growth.

Summary

Out of 48,546 condition-relevant adverse event reports for atorvastatin in the FDA AEMS database (from 123,129 total female-patient reports), abdominal and pelvic pain reports (abdominal pain upper n=6, abdominal pain n=4, abdominal discomfort n=2) combined with inflammatory signals (swelling n=4, oedema peripheral n=4, joint swelling n=2) mirror adenomyosis symptom profiles. Atorvastatin's anti-fibrotic effects through TGF-β and mevalonate pathway modulation are mechanistically relevant to adenomyosis-associated uterine fibrosis. Full-scale analysis of all reports may reveal additional patterns.

Summary

Out of 46,392 condition-relevant adverse event reports for rosuvastatin in the FDA AEMS database (from 107,207 total female-patient reports), abdominal and pelvic signals (abdominal pain upper n=7, abdominal pain n=5, abdominal distension n=3, uterine haemorrhage n=1, uterine cyst n=1) combined with inflammatory reactions (inflammation n=2, swelling n=6, oedema peripheral n=2) are consistent with adenomyosis-related presentations. The shared estrogen-driven and inflammatory pathways with endometriosis make these signals mechanistically relevant. Full-scale analysis of all reports may reveal additional patterns.

Summary

Out of 50,392 condition-relevant adverse event reports for simvastatin in the FDA AEMS database (from 126,236 total female-patient reports), a notable cluster of inflammatory and pain reactions (inflammation n=6, abdominal pain n=6, abdominal distension n=5, oedema peripheral n=2, joint swelling n=2) alongside a direct endometriosis report and uterine leiomyoma report suggests relevance to adenomyosis through shared estrogen-driven inflammatory pathways. The anti-inflammatory and anti-fibrotic properties of statins via mevalonate pathway inhibition are mechanistically aligned with adenomyosis pathology. Full-scale analysis of all reports may reveal additional patterns.

Summary

Out of 3,742 condition-relevant adverse event reports for pravastatin in the FDA AEMS database (from 10,007 total female-patient reports), the convergence of abdominal pain (n=6), inflammatory signals (peripheral swelling n=5, oedema peripheral n=4), and back pain (n=9) alongside menstrual irregularity (n=1) and hysterectomy (n=1) is relevant to adenomyosis, which shares estrogen-driven inflammatory pathways with endometriosis. Pravastatin's demonstrated anti-fibrotic activity supports mechanistic relevance. Full-scale analysis of all reports may reveal additional patterns.

Summary

Out of 25,166 condition-relevant adverse event reports for tirzepatide in the FDA AEMS database (from 74,456 total female-patient reports), pain and inflammatory signals overlap with adenomyosis-relevant pathways, including abdominal pain (n=2), abdominal pain upper (n=4), abdominal discomfort (n=6), abdominal distension (n=4), back pain (n=10), and pelvic-region pain signals, alongside inflammatory markers. As adenomyosis shares the estrogen-dependent NF-κB inflammatory pathway with endometriosis, the same GLP-1/GIP anti-inflammatory mechanism is applicable. Full-scale analysis of all reports may reveal additional patterns.

Summary

Out of 12,085 condition-relevant adverse event reports for liraglutide in the FDA AEMS database (from 29,717 total female-patient reports), pain and inflammatory signals included abdominal pain (n=11), gastrointestinal pain (n=7), abdominal pain upper (n=6), abdominal discomfort (n=2), abdominal distension (n=2), back pain (n=1), peripheral swelling (n=3), and vaginal ulceration (n=1), alongside uterine-relevant findings including uterine leiomyoma (n=1) and uterine cancer (n=1). The uterine leiomyoma report is notable given the overlap between fibroids and adenomyosis in estrogen-driven myometrial pathology. Full-scale analysis of all reports may reveal additional patterns.

Summary

Out of 19,586 condition-relevant adverse event reports for semaglutide in the FDA AEMS database (from 47,253 total female-patient reports), abdominal and pelvic pain signals were prominent including abdominal pain (n=12), abdominal pain upper (n=12), abdominal distension (n=6), and abdominal discomfort (n=5), alongside inflammatory signals. The adenomyosis-relevant pain and inflammatory profile mirrors the endometriosis signal given their shared estrogen-driven inflammatory pathology, and GLP-1 receptor-mediated NF-κB suppression could theoretically modulate myometrial inflammatory processes. Full-scale analysis of all reports may reveal additional patterns.

Summary

Out of 4,176 condition-relevant adverse event reports for pramipexole in the FDA AEMS database (from 10,301 total female-patient reports), the same pain and inflammatory pattern seen in the endometriosis signal — pain (n=22), abdominal pain (n=6), peripheral swelling (n=10), oedema peripheral (n=7) — is equally relevant to adenomyosis through shared estrogen-dependent inflammatory pathways. Pramipexole's D3 receptor modulation of central pain sensitization and neuroinflammation applies to adenomyosis-associated dysmenorrhoea and chronic pelvic pain via the same descending pain inhibitory mechanisms. Full-scale analysis of all reports may reveal additional patterns.

Summary

Out of 4,313 condition-relevant adverse event reports for ropinirole in the FDA AEMS database (from 10,302 total female-patient reports), the abdominal/pelvic pain and inflammatory signals (abdominal pain n=6, abdominal distension n=5, peripheral swelling n=7, oedema n=4) alongside uterine-specific findings (uterine leiomyoma n=1, uterine polyp n=1, dysmenorrhoea n=1) parallel the endometriosis signal and are equally applicable to adenomyosis through shared estrogen-dependent uterine pathology. Dopaminergic modulation of myometrial pain processing and uterine inflammatory milieu is mechanistically relevant. Full-scale analysis of all reports may reveal additional patterns.

Summary

Out of 36,976 condition-relevant adverse event reports for escitalopram in the FDA AEMS database (from 85,593 total female-patient reports), pain and uterine signals relevant to adenomyosis were identified including abdominal pain (n=9), abdominal discomfort (n=6), pain (n=17), uterine perforation (n=4), uterine haemorrhage (n=1), uterine leiomyoma (n=1), uterine cyst (n=1), alongside menorrhagia (n=1) and depression (n=12). The concentrated uterine pathology signals combined with abdominal pain suggest a population with myometrial disease consistent with adenomyosis. Full-scale analysis of all reports may reveal additional patterns.

Summary

Out of 34,200 condition-relevant adverse event reports for citalopram in the FDA AEMS database (from 83,257 total female-patient reports), pain and uterine signals relevant to adenomyosis were identified including pelvic pain (n=3), abdominal pain (n=10), abdominal distension (n=5), uterine perforation (n=3), uterine hypertonus (n=1), vaginal haemorrhage (n=2), alongside depression (n=18) and fatigue (n=14). The uterine hypertonus signal is particularly relevant to adenomyosis-associated dysfunctional myometrial contractility. Full-scale analysis of all reports may reveal additional patterns.

Summary

Out of 35,251 condition-relevant adverse event reports for fluoxetine in the FDA AEMS database (from 83,971 total female-patient reports), pain and uterine signals relevant to adenomyosis were identified including abdominal pain (n=11), pain (n=16), uterine perforation (n=2), uterine leiomyoma (n=1), dysfunctional uterine bleeding (n=1), menorrhagia (n=3), alongside depression (n=17) and anxiety (n=14). These signals overlap the endometriosis-adenomyosis shared pathway and suggest serotonergic modulation may affect uterine pain processing and mood comorbidity in adenomyosis. Full-scale analysis of all reports may reveal additional patterns.

Summary

Out of 54,612 condition-relevant adverse event reports for sertraline in the FDA AEMS database (from 130,278 total female-patient reports), pain signals relevant to adenomyosis were identified including abdominal pain (n=5), abdominal pain upper (n=8), uterine perforation (n=3), uterine cyst (n=1), uterine leiomyoma (n=1), alongside depression (n=16) and menstrual disturbances (menorrhagia n=1, metrorrhagia n=1). These signals overlap with the endometriosis-adenomyosis shared estrogen-driven inflammatory pathway, and the mood comorbidity burden characteristic of adenomyosis. Full-scale analysis of all reports may reveal additional patterns.

Summary

Out of 38,880 condition-relevant adverse event reports for naproxen in the FDA AEMS database (from 85,294 total female-patient reports), uterine-relevant signals (uterine haemorrhage n=1, uterine leiomyoma n=1) co-occur with abdominal/pelvic pain (abdominal pain n=14, pelvic pain n=2), menorrhagia (n=1), and inflammatory markers, forming a cluster relevant to adenomyosis. The shared estrogen-prostaglandin pathway with endometriosis makes these signals cross-applicable. Full-scale analysis of all reports may reveal additional patterns.

Summary

Out of 36,972 condition-relevant adverse event reports for celecoxib in the FDA AEMS database (from 83,065 total female-patient reports), uterine structural signals (uterine prolapse n=1, uterine malposition n=1, uterine disorder n=1) alongside pain and inflammatory markers mirror the endometriosis-adenomyosis pathological overlap. Celecoxib's targeted COX-2 inhibition is mechanistically relevant to adenomyosis where COX-2 overexpression drives myometrial inflammation. Full-scale analysis of all reports may reveal additional patterns.

Summary

Out of 37,836 condition-relevant adverse event reports for diclofenac in the FDA AEMS database (from 86,286 total female-patient reports), uterine-relevant signals (uterine perforation n=1) alongside abdominal/pelvic pain (abdominal pain n=2, abdominal pain upper n=7, abdominal discomfort n=4) and inflammatory signs are relevant to adenomyosis. The shared pathological pathways with the endometriosis signal in this same dataset strengthen the cross-condition relevance. Full-scale analysis of all reports may reveal additional patterns.

Summary

Out of 17,165 condition-relevant adverse event reports for meloxicam in the FDA AEMS database (from 37,086 total female-patient reports), a direct adenomyosis report (n=1) co-occurs with endometriosis-relevant signals including uterine leiomyoma (n=1), uterine polyp (n=1), ovarian cyst (n=1), menorrhagia (n=1), vaginal haemorrhage (n=2), abdominal pain (n=7), and substantial inflammatory markers (peripheral swelling n=9, oedema n=3, inflammatory marker increased n=1). This is one of few NSAID datasets with a direct adenomyosis adverse event report. Full-scale analysis of all reports may reveal additional patterns.

Summary

Out of 68,147 condition-relevant adverse event reports for ibuprofen in the FDA AEMS database (from 159,407 total female-patient reports), pelvic pain, uterine pain, menorrhagia, and dysmenorrhoea reports are present alongside uterine structural pathology signals (uterine fibrosis, uterine leiomyoma), consistent with adenomyosis-relevant symptomatology persisting despite NSAID therapy. The overlap with endometriosis-related signals underscores shared estrogen-driven inflammatory pathways. Full-scale analysis of all reports may reveal additional patterns.

Summary

Out of 8,735 condition-relevant adverse event reports for exemestane in the FDA AEMS database (from 18,954 total female-patient reports), the same estrogen-suppressive signals relevant to endometriosis — including abdominal pain (n=3), abdominal pain upper (n=5), pelvic pain (n=1), uterine haemorrhage (n=1), and inflammatory markers (oedema peripheral n=4, mucosal inflammation n=3, inflammation n=2) — apply to adenomyosis which shares aromatase overexpression in ectopic endometrial tissue within the myometrium. Exemestane's irreversible aromatase inactivation may provide more sustained suppression of local myometrial estrogen production than reversible inhibitors. Full-scale analysis of all reports may reveal additional patterns.

Summary

Out of 89,421 condition-relevant adverse event reports for metformin in the FDA AEMS database (from 212,759 total female-patient reports), abdominal and pelvic pain signals combined with inflammatory markers and uterine-relevant events (uterine perforation, hysterectomy) are present. Metformin's AMPK-mediated suppression of estrogen biosynthesis and NF-κB-driven inflammation is directly relevant to adenomyosis, which shares estrogen-dependent inflammatory pathways with endometriosis. Full-scale analysis of all reports may reveal additional patterns.

Summary

Out of 28,321 condition-relevant adverse event reports for spironolactone in the FDA AEMS database (from 73,834 total female-patient reports), pelvic pain (n=2), abdominal pain (n=4), abdominal pain lower (n=2), menorrhagia (n=1), uterine haemorrhage (n=1), and inflammatory edema signals (peripheral oedema n=8, oedema n=6) were observed. These pain and uterine-hemorrhage patterns are relevant to adenomyosis, which shares estrogen-driven inflammatory pathways with endometriosis, and spironolactone's hormonal modulation could influence myometrial tissue biology. Full-scale analysis of all reports may reveal additional patterns.

Summary

Out of 8,493 condition-relevant adverse event reports for naltrexone in the FDA AEMS database (from 18,974 total female-patient reports), abdominal and uterine pain signals (abdominal pain n=6, abdominal pain upper n=6, pain n=7, abdominal discomfort n=4) combined with uterine leiomyoma reports (n=2), metrorrhagia (n=1), and inflammatory markers suggest relevance to adenomyosis, which shares estrogen-dependent uterine pathology with endometriosis. Opioid receptor expression in myometrial tissue means naltrexone's receptor blockade could modulate uterine smooth muscle contractility and local inflammatory tone. Full-scale analysis of all reports may reveal additional patterns.